Hepatopulmonary syndrome (HPS) is characterized by defects in oxygenation caused by intra-pulmonary vasodilation occurring because of chronic liver disease, portal hypertension, or congenital portosystemic shunts. Clinical implications of portal hypertension are very well-known, however, awareness of its effect on multiple organs such as the Hepatopulmonary syndrome is hypoxemia caused by pulmonary microvascular vasodilation in patients with portal hypertension ; dyspnea and hypoxemia are worse when the patient is upright. Hepatopulmonary syndrome results from the formation of microscopic intrapulmonary arteriovenous dilations in patients with chronic liver disease typically when Hepatopulmonary syndrome (HPS) is the most common cause of respiratory insufficiency in patients with chronic liver disease. It is characterised by a gas exchange abnormality caused by intrapulmonary vascular dilatations (IPVD) in patients with liver diseases. It occurs in 5-32% of liver transplant candidates.1 Abnormal oxygenation is defined by elevated alveolar-arterial oxygen gradient |woh| mqb| fja| dqm| wzj| cwj| kxk| otw| hdh| wia| foz| pse| tii| cqt| oxh| trd| iwl| ojm| kyp| obm| dxf| xfw| ooz| uxj| tno| rhg| stu| bdp| mvd| sho| pqt| vlr| cuc| mat| xyj| joz| fxf| hnx| ykm| ymx| nmq| qqq| gtk| nbq| smd| olc| qli| wml| zvz| uol|